Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2015 (2015), Article ID 835952, 5 pages
http://dx.doi.org/10.1155/2015/835952
Case Report

Left Ventricular Thrombus as a Complication of Clozapine-Induced Cardiomyopathy: A Case Report and Brief Literature Review

1Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Fargo, ND 58102, USA
2Department of Cardiology, Sanford Health, Fargo, ND 58102, USA
3Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, ND 58102, USA

Received 2 July 2015; Accepted 7 November 2015

Academic Editor: Tayfun Sahin

Copyright © 2015 Shahbaz A. Malik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Nielsen, P. Damkier, H. Lublin, and D. Taylor, “Optimizing clozapine treatment,” Acta Psychiatrica Scandinavica, vol. 123, no. 6, pp. 411–422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Kalra and I.-K. Jang, “Prevalence of early left ventricular thrombus after primary coronary intervention for acute myocardial infarction,” Journal of Thrombosis and Thrombolysis, vol. 10, no. 2, pp. 133–136, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. V. G. Kalaria, M. R. Passannante, T. Shah, K. Modi, and A. B. Weisse, “Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy,” American Heart Journal, vol. 135, no. 2, pp. 215–220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Walker, L. L. Lanza, F. Arellano, and K. J. Rothman, “Mortality in current and former users of clozapine,” Epidemiology, vol. 8, no. 6, pp. 671–677, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Vera, L. Rezende, V. Molina, and J. Sanz-Fuentenebro, “Clozapine as treatment of first choice in first psychotic episodes. What do we know?” Actas Españolas de Psiquiatría, vol. 40, no. 5, pp. 281–289, 2012. View at Google Scholar · View at Scopus
  6. C. Murray and A. Lopez, Eds., The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Harvard University Press, Cambridge, Mass, USA, 1996.
  7. L. Voruganti, L. Cortese, L. Oyewumi, Z. Cernovsky, S. Zirul, and A. Awad, “Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life,” Schizophrenia Research, vol. 43, no. 2-3, pp. 135–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine,” Archives of General Psychiatry, vol. 45, no. 9, pp. 789–796, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Kane, “Treatment-resistant schizophrenic patients,” Journal of Clinical Psychiatry, vol. 57, supplement 9, pp. 35–40, 1996. View at Google Scholar · View at Scopus
  10. S. W. Lewis, T. R. E. Barnes, L. Davies et al., “Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia,” Schizophrenia Bulletin, vol. 32, no. 4, pp. 715–723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Hennen and R. J. Baldessarini, “Suicidal risk during treatment with clozapine: a meta-analysis,” Schizophrenia Research, vol. 73, no. 2-3, pp. 139–145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Coulter, A. Bate, R. H. B. Meyboom, M. Lindquist, and I. R. Edwards, “Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study,” British Medical Journal, vol. 322, no. 7296, pp. 1207–1209, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Wehmeier, P. Heiser, and H. Remschmidt, “Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine,” Journal of Clinical Pharmacy and Therapeutics, vol. 30, no. 1, pp. 91–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Wooltorton, “Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity,” Canadian Medical Association Journal, vol. 166, no. 9, pp. 1185–1186, 2002. View at Google Scholar · View at Scopus
  15. M. Alawami, C. Wasywich, A. Cicovic, and C. Kenedi, “A systematic review of clozapine induced cardiomyopathy,” International Journal of Cardiology, vol. 176, no. 2, pp. 315–320, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. G. Fontana and B. Sümegi, Association of Clozaril (Clozapine) with Cardiovascular Toxicity, Novartis Pharmaceuticals Canada, Dorval, Canada, 2002.
  17. G. Friman, L. Wesslen, J. Fohlman, J. Karjalainen, and C. Rolf, “The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy,” European Heart Journal, vol. 16, pp. 36–41, 1995. View at Publisher · View at Google Scholar
  18. D. L. Youssef, P. Narayanan, and N. Gill, “Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia,” Australasian Psychiatry, 2015. View at Publisher · View at Google Scholar
  19. L. La Grenade, D. Graham, and A. Trontell, “Myocarditis and cardiomyopathy associated with clozapine use in the United States,” The New England Journal of Medicine, vol. 345, no. 3, pp. 224–225, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. J. G. Kilian, K. Kerr, C. Lawrence, and D. S. Celermajer, “Myocarditis and cardiomyopathy associated with clozapine,” The Lancet, vol. 354, no. 9193, pp. 1841–1845, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. K. L. D. Phan and S. F. Taylor, “Clozapine-associated cardiomyopathy,” Psychosomatics, vol. 43, article 248, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Hoehns, M. M. Fouts, M. W. Kelly, and K. B. Tu, “Sudden cardiac death with clozapine and sertraline combination,” Annals of Pharmacotherapy, vol. 35, no. 7-8, pp. 862–866, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Rostagno, S. Domenichetti, F. Pastorelli, and G. F. Gensini, “Clozapine associated cardiomyopathy: a cluster of 3 cases,” Internal and Emergency Medicine, vol. 6, no. 3, pp. 281–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Chow, T. Yeoh, A. C. Ng et al., “Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study,” Open Heart, vol. 1, no. 1, Article ID e000030, 2014. View at Publisher · View at Google Scholar
  25. D. B. Merrill, G. W. Dec, and D. C. Goff, “Adverse cardiac effects associated with clozapine,” Journal of Clinical Psychopharmacology, vol. 25, no. 1, pp. 32–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. J. Leo, J. L. Kreeger, and K. Y. Kim, “Cardiomyopathy associated with clozapine,” Annals of Pharmacotherapy, vol. 30, no. 6, pp. 603–605, 1996. View at Google Scholar · View at Scopus
  27. R. Sagar, N. Berry, R. Sadhu, and S. Mishra, “Clozapine-induced cardiomyopathy presenting as panic attacks,” Journal of Psychiatric Practice, vol. 14, no. 3, pp. 182–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. C. A. Pastor and M. Mehta, “Masked clozapine-induced cardiomyopathy,” Journal of the American Board of Family Medicine, vol. 21, no. 1, pp. 70–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Reinders, W. Parsonage, D. Lange, J. M. Potter, and S. Plever, “Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service,” Australian and New Zealand Journal of Psychiatry, vol. 38, no. 11-12, pp. 915–922, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Rostagno, G. Di Norscia, G. F. Placidi, and G. F. Gensini, “Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine,” General Hospital Psychiatry, vol. 30, no. 3, pp. 280–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. R. Conley, “Optimizing treatment with clozapine,” Journal of Clinical Psychiatry, vol. 59, supplement 3, pp. 44–48, 1998. View at Google Scholar · View at Scopus